Oncothyreon Inc (USA) Logo Image

Oncothyreon Inc (USA)

Oncothyreon Inc (USA) has reached its limit for report views.

Please check back to see if Oncothyreon Inc (USA) has upgraded their profile page to allow their financial information to be viewed. In the meantime, here are a few annual reports from similar companies.

Most Recent Annual Report

2015 Annual Report and Form 10K

Oncothyreon Inc (USA)

Oncothyreon Inc (USA) does not currently have any hardcopy reports available on AnnualReports.com. Click the button below to be notified when hardcopies become available.



About Oncothyreon Inc (USA)

Oncothyreon Inc., a clinical-stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of cancer. Its clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, which is in two Phase 1b trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin; and ONT-10, a therapeutic vaccine in Phase 1 trial targeting the Mucin 1 peptide antigen (MUC1) for use in various cancer indications, including breast, thyroid, colon, stomach, pancreas, ovarian, and prostate, as well as certain types of lung cancer.

Ticker:
ONTY
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol